Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...
Stockpickers: Bitterest pill for pharmaceutical groups to swallow
A new Alzheimer’s treatment from US firm Eli Lilly was approved for use this week by the UK drug regulator MHRA, although disappointingly for its maker, the drug won’t be available on the NHS as it ...
Campaign US4h
How Lilly is building a brand people trust
Lina Polimeni, chief corporate brand officer at Lilly, notes that public perception of the company has historically been ...
Lilly's Ebglyss shown to be effective in former Dupixent users
Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...
Eli Lilly price target raised to $1,250 from $1,060 at Citi
Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...
Zacks.com on MSN6h
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
New Alzheimer’s drug approved in UK, but government won’t pay for it
The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months.View on ...
Pharma’s race for obesity drugs is still hotting up
The UK’s AstraZeneca, which is working on an oral GLP-1, also views the drugs as part of a combination strategy. In other ...
Second Alzheimer’s drug rejected by NICE on the same day it is approved in the UK
NICE’s decisions for both drugs are not final and are pending more evidence. Credit: Art_Photo via Shutterstock. · Clinical ...
A non-opioid pain med, a COVID-flu shot combo, and more: 7 drug launches to watch in 2025
As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...
STAT10h
Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight
A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...
The Financial Express11h
Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection: GlobalData
There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.